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Abstract: The preparation of nanomedicines can be achived using a host of methods ranging from wet-chemical 
approaches to more engineering related techniques. As a maturing branch of  nanotechnology, nanomedcines are 
being tailored to serve multiple pharmaceutic and biomedical related funcitons (e.g. targeted delivery, imaging, 
healing, sensing) which may require the utilisaiton of one or more actives or excipients. In some instances, handling 
of materials (such as sensitive biomolecules or active pharmaceutical ingredient) becomes a limiting factor along 
with issues  related to fabrication steps (loss or degradation of active components and functional materials), 
deposition location & procedure (removal of formed structures), process environment sensitivity and scale-up 
potential. This short review focuses on the electrohydrodynamic preparation of emerging nanomedicines that have 
potential to serve as therapeutic platforms. An insight into the underpinning process (jet-formation), related 
paramerts (material and process) and strucutral outcomes (particles and fibres) is given in relation to highlighted 
research. The ambient temperature processing, user friendly preparation and present industrial scale up potential 
(now in kg/hr) make  such processes valuable in the preparation of future nano-scaled and sensitive dosage forms. 
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INTRODUCTION 
Nanomedicine is an evolving branch of nanotechnology that includes the development of nanostructures and 
nanoanalytical systems to create new diagnostics and therapeutics for medical applications [1]. The utilisation of 
these materials has led to advances in targeted delivery (drugs to a specific cell or tissue), enhanced delivery of 
poorly water-soluble drugs, co-delivery of two or more drugs (combination therapy) or even as diagnostic tools [2]. 
However, the preparation of effective, stable and safe drug delivery systems still represents a significant ongoing 
challenge in medicine and pharmaceutical sciences [3,4]. 
Several methods have been developed and adapted in recent times for the preparation of nanoparticles. Such 
structures (utilising polymers) are prepared from biodegradable and biocompatible materials where the active 
pharmaceutical ingredient (API) is encapsulated or conjugated with the polymeric matrix system. Common methods 
of preparation include solvent evaporation [4,5], nanoprecipitation or solvent displacement method [6,7], 
emulsification [8,9], dialysis [10] and supercritical fluid technology [11,12]. Electrohydrodynamic atomisation (EHDA) 
techniques (as applied to drug delivery or charged jets resulting in the formation of micrometer and 
nanometer scaled architectures. Technological variations to these processes (e.g. by using a variety of processing 
heads), combined with differences in physical properties of selected and number of liquid (or suspension) phase 
materials (e.g. formulations) give rise to potential morphological variations [13]. These processes offer a series of 
advanatges over conventional material and pharmaceutical prepation routes and wil therefore provide several 
opportunities when coupled to sensitive APIs and biological molecules of significance [14,15]. pharmaceutics) are a 
series of processes driven by electrically charged jets resulting in the formation of micrometer and nanometer scaled 
architectures. Technological variations to these processes (e.g. by using a variety of processing heads), combined 
with differences in physical properties of selected and number of liquid (or suspension) phase materials (e.g. 
formulations) give rise to potential morphological variations [13]. These processes offer a series of advanatges over 
conventional material and pharmaceutical prepation routes and wil therefore provide several opportunities when 
coupled to sensitive APIs and biological molecules of significance [14,15]. 
ELECTROHYDRODYNAMIC ATOMISATION (EHDA) PROCESS 
The underlying principle allows the generation of micrometer and nanometer scaled morphologies which are of 
signifncat interest in the pharmaceutical arena. EHDA is described by Grace and Marijnissen (1994) as tiny droplets 
obtained from the electrically forced (electro) break-up of a moving (dynamic) liquid (hydro) at a controlled flow rate 
through a capillary needle fixed at several kilovolts in relation to a ground electrode few centimetres away [16]. The 
EHDA process is a well-known physical process where a liquid jet breaks up into droplets due to the electric and 
mechanical forces [17] (Fig. 1). Depending on the magnitiude of the electrical stress, and the kinetic energy of liquid 
jet leaving the nozzle, a series of spraying modes can be obtained. 
In recent years, EHDA methods have developed considerably from the early conceptual experimentations.  These 
exist as electrospraying (particle formation), electrospinning (fibre generation), co-axial generation and direct writing 
[18-21]. Generation of very fine droplets with near uniform size distribution alongside ambient temperature 
processing, when compared to other methods, which require very small orifices, are advantages of this process. 
Rayleigh made the earliest observations on the instability due to the electric charges on drops and jets, and 
suggested the conditions for a drop or jet to become unstable. The stability of the drop/jet is dependent on the 
balance of forces, i.e. the outward electrical stresses tending to disrupt the drop and the counteracting surface 
tension forces trying to hold the drop together [22,23]. Zeleny pioneered the experimental studies of EHDA based on 
Rayleigh’s theories, observed different modes of spraying at the exit of the capillary, which was exposed to an 
external electric field and was able to produce a qualitative description of the process. This was based on factors 
such as liquid flow rate from the formulation capillary exit and the applied voltage, and subsequently imaged these 
different modes [24,25] (common examples shown in Fig. 2). Some of the key benefits of this process are: ambient 
temperature method (as opposed to melt spinning), scalability (now in kg/hr), multiple parameters enabling 
morphology variaiton if one is problematic (e.g. increasing the flow rate if the viscosity is too high) and low driving 
pressure (low flow rates accomodated when compared to pressures required in spray drying). 
EHDA CONFIGURATION 
The most typical nomenclature for the spraying heads in EHDA systems is single needle/nozzle or capillary (or often 
just termed without co-axial). This defines the number of electrically conducting needles/nozzles or capillaries (e.g. 
stainless steel is generally used) through which media is perfused. 
An electric field is applied to the needle (using a voltage supply, typically up to 30 kV or higher if multiple headed 
devices are being used for scale-up). Media is perfused into the needles using specifically controlled infusion pumps 
(directly coupled to the processing needle with silicon or other formulation transporting tubing). In addition, the 
process is varied by the medium in question and its physical properties-especially viscoelastic properties. Under 
atomising conditions the resulting droplets or fibres (spraying and spinning, respectively) are electrically charged, 
thus enabling them to be guided and focused easily on to a collecting substrate or directly into a medium, minimising 
droplet agglomeration (also due to inter-structural charges). Generation of very fine structures with near-uniform 
size distribution is an advantage of this process. In some processes, a ring or point like ground electrode is placed a 
few centimetres below the tip of the needle to improve the stability of the jetting mode (Fig. 3). 
 
 
Critical Material Factors 
Both single and coaxial needle atomization processes are able to produce nano-scaled pharmaceutical dosage forms 
via a single step process, providing control over particle size, size distribution and shape under ambient conditions. 
The size and size distribution of the particles to be generated could be systematically controlled over a range of 
operating parameters such as flow rate and applied voltage [26,27]. These can also affect the mode of jetting but 
when optimised (stable jetting e.g. Taylor cone [28]) EHDA translates into a robust and versatile method for 
generating advanced drug delivery systems comprising APIs and currently utilised pharmaceutical excipients 
[29,30,31]. As well as generating particles with a narrow size distribution by controlling the processing parameters, 
material (formulation) properties such as density, viscosity, electrical conductivity and surface tension are also 
crucial elements of the process and will impact structures generated [32,33,34]. 
Viscosity is a fundamental liquid property, which plays a significant role in the jet break-up process by influencing the 
hydrodynamic component of the EHDA modes and therefore affects the size of the produced structures [35]. For 
example, a study found that an increase in viscosity over three orders of magnitude had a dramatic (increasing) 
effect on the size of particles obtained [36]. Liquid electrical conductivity is the most important property for 
electrospraying in the stable-jetting mode as it enables jet formation. However, if this is too high, EHDA becomes 
compromised due to coronal discharge before attaining the required applied voltage for the stable jet mode. Liquids 
with low conductivity (insulators) cannot be subjected to EHDA alone (e.g., olive oil) although they can be atomised 
by artificially increasing their electrical conductivities with additives such as ethanol or by combining them with 
electrically conductive liquids in a coaxial system [35]. The lowest limitation of conductivity is 10-11 Sm-1 [37]. The 
density of the liquid plays a role in determining the jet diameter of the cone-jet mode. When the viscosity and 
conductivity of the liquid (formulation) are large enough, the electrical charge is transmitted throughout the jet 
section by viscous forces. However, the viscous force depends on the density of the liquid [38]. 
CRITICAL EHDA PROCESSING FACTORS 
Applied voltage is a key variable in establishing the cone-jet (stable jetting) mode and can prevail within a range of 
values [39]. The electric field between the needle and the ground electrode is a key parameter in controlling the 
process of EHDA and this is controlled mainly by the applied voltage and the configuration of the ground electrode. A 
higher applied voltage leads to a stronger atomisation effect on the liquid, thus the atomisation of the liquid takes 
place mainly due to electrical forces produced by this field. In a specific voltage range, the meniscus of liquid 
becomes conical and stationary and below this voltage range, the spray always operates in pulsating mode [38]. 
Every liquid has a minimum flow rate (infusion into the processing nozzle), below which a stable cone-jet mode 
cannot exist [40]. The droplet size distribution produced using EHDA (in the cone-jet mode) depends on the diameter 
of the jet and jet break-up into droplets. At this minimum flow rate, the jet breaks up due to varicose instabilities 
(asymmetrical instabilities). Increasing the flow rate leads to an increase in both current and charge across the liquid 
cone. Once this is beyond the critical surface charge, lateral instabilities also contribute towards the jet break-up. 
These are termed kink instabilities and these lead to an increase in the size distribution (broader) of main droplets 
[40]. 
STRUCTURAL VARIATIONS WITH EHDA FORMATION 
Advanced materials (materials possessing superior mechanical, chemical properties or those which also have other 
functional roles e.g. stimulus responsive materials) can be combined together by innovative methods to generate 
novel or specific active containing materials using EHDA, which is a robust process allowing a more broader range of 
structures (particles (solid and hollow), layered-fibrous structures and bubbles) [41,42,43,44]. This is based on the 
viscoelastic (fibres (high) to particles (low)) and phase (porosity control based on solvent volatility and degree of 
solubility) properties of materials, device configuration, flow rates and applied voltage. The resulting structures can 
also be tailored to fit within a specific size band (e.g. nano or micro scale) based on the concentration of polymer in 
the solution or the applied voltage during jetting of the formulation (e.g. more viscous solutions can yield larger 
droplets and fibres in addition to higher voltages resulting in finer structures) [45,46]. In addition to structure size, 
the surface (roughness, porosity, controlled layering) can also be engineered to achieve a desirable state. Structures 
can also be formed intermittently (Fig. 4). For example, in electrospinning bead formation [47] can result which is    
 
observed as an intermediate between electrospun and electrosprayed structures. The particle shape can also be  
controlled by reaching a specific operating voltageflow rate parametric window (aspect ratio variations), which may 
have further potential in targeted and controlled drug delivery. Advance in shape–related drug delivery is promising. 
In-vitro studies have demonstrated enhanced organelle targeting at the cellular level, enhanced antibody specificity 
and controlled cellular internalisation [48-50] based on shape parameters (aspect-ratio). The opportunity to prepare 
similar structures using EHDA has been demonstrated but in-vitro and in-vivo testing remains to be explored in 
depth [51]. 
EHDA PREPARATION OF NANOMEDICINES 
EHDA techniques have been utilised in the preparation of a series of prospective nanomedicines based on the 
aforementioned underpinning principles and specific material properties. Advances have already been 
demonstrated in the preparation of nanoparticles and quantum dots [52-55], to deposit ultra-thin films of inorganic, 
organic and biological materials [56, 57], sorting nanoparticles based on their sizes [58] and assisting in the 
dispersion and delivery of nanomaterials [59,60]. 
NANOPARTICLES 
EHDA engineered nanoparticles have been adapted for a series of proof of concept studies related to numerous 
conditions and disease states but are yet to reach the clinic. Some examples of these recent studies are given below.  
Chronic Illness Treatment 
The EHDA process can be used to produce polymeric nanoparticles (containing active embedded within a polymeric 
matrix system) including both hydrophilic and hydrophobic drugs with little adverse impact on the functionality 
(degradation) of the selected drug. In addition to this benefit, enhanced encapsulation efficacy is also achievable [13, 
61]. 
For example, using a co-axial electrospraying technique (multiple individual material flow to be incorporated into the 
same nanoparticle architecture) insulin-loaded PLGA (Poly lactic-co-glycolic acid) copolymer nanoparticles have been 
produced with an encapsulation efficiency of 80 +/- 4.1 %. This process also utilised excipients to retard the burst 
release of insulin from the PLGA polymer system. One of the key issues with insulin encapsulation is its stability 
during preparation. However, this was not hindered under one-step EHDA preparation conditions. This single step 
process yielded 85% of nanoparticles, which were less than 100 nm in size [62]. Potential EHDA applications in 
pulmonary medicine have also been researched. The actives beclomethasone- dipropionate and salbutamol-sulfate 
have been successfully loaded into an associated biodegradable polymer  Polylactide (PLA). In this instance, the 
average size of particles was 200 nm, which were generated under the stable cone-jet mode [61]. Within the same 
remit, coaxially aligned needles were optimized to electrospray PLGA particles coated with drugs possessing varying 
hydrophobicities. The drugs budesonide and EGCG (epigallocatechin gallate) were used and resulting particles 
demonstrated sizes between 165 nm-1.2 μm and 158–170 nm, respectively. Budesonide is a class of steroidal 
hormones (glucocorticoid) to treat asthma and non-infectious rhinitis and it researched in the chemoprevention of 
lung cancer [63, 64]. 
Cancer Therapeutics 
The ongoing development for the treatment of cancers using advanced novel synthetic products represents one face 
of product development. An advantage offered by nanoscaled structures provides a gateway to more effective 
treatment. The anti-cancer drug paclitaxel, in this instance for treating C6 glioma, demonstrated an encapsulation 
efficiency of ∼80% [65] when prepared using EHDA. The processes demonstrated the generation of nanometer and 
micrometer scaled particles, while also focusing on ability to vary their shape and structure (corrugated, doughnut 
and spherical). Another interesting feature of this study was that an in-vitro release over 30 days was demonstrated. 
While the structure of particles can be varied, the coating of materials can also be used to target specific sites. For 
example, in the potential treatment of pancreatic cancer a co-axial needle system has been used in an EHDA set-up 
to prepare coreshelled folate-chitosan particles with the active gemcitabine [66]. The particle size was 200-300nm 
and the high encapsulation efficiencies demonstrated remarkable cytotoxicity towards selected cell lines (BXPC3). In 
addition to these, more coarse (~500nm) nanoparticle systems have been developed using EHDA to prepare 
anticancer therapies involving drugs such as tamoxifen [67]. 
The anti-cancer drug hydroxycamptothecin has been formulated into acid-liable nanoparticles (based on acid labile 
segments and galactose components) using the electrospraying technique resulting in particles with a mean size of 
230 nm. As was found with several other examples of EHDA fabricated drug-particle systems, the drug-loading 
efficacy demonstrated a marked improvement when compared to other preparation techniques. In addition, these 
nanoparticles demonstrated prolonged drug release (increased circulation time) making them good candidates for a 
sustained system. In comparison, they also demonstrate reduced side effects [68]. 
While drug encapsulation and its efficiency have proven to be an advantageous outcome when using the 
electrospraying process, researchers have also utilised other features of the nanoscale to enhance drug-delivery and 
targeting science. For example, directly linked with potential cancer treatment imaging modalities have also been 
demonstrated on the nanoscale. The co-axial electrospray system provides a route to coat existing nanoparticles as 
well as preparing multi-coated nanoparticles from pure solutions/mixtures. Iron-oxide (magnetic) nanoparticles with 
a mean size of 8.2 nm have been used directly in the formulation medium (oleic acid) for the inner needle of the co-
axial device. In this instance, polysorbate80 was used as the coating material (outer needle). Under EHDA conditions, 
a multi-layered magnetic nanoparticle system (comprising particle layered with oleic acid, which in turn layered with 
polysorbate80) was achieved. The mean size of the droplet structures was 96.1 nm. However once deposited into an 
aqueous phase, the size of these structures was approximately 10.7 nm with the outer polysorbate80 layer 
contributing 1.25 nm. The monodisperse nature of these nanoparticles enhanced the MR signal (which is crucial for 
imaging) and using the same system in a xenograft mouse model the imaging of a tumour site was clearly 
demonstrated [69]. Based on the multiple layering model demonstrated it is possible to combine other actives and 
excipients in the preparation of multi-functional nanoparticles. 
Gene and Peptide Delivery 
Electrospray can be used to deliver genes into microorganisms. Unlike conventional EHDA particle preparation 
systems based on a polymer-drug solution, it is possible to use nanoparticles as a colloidal-drug system (or 
colloidalgene system) to be processed under EHDA conditions. For example, gold nanoparticles (50 nm) were 
sprayed alongside the plasmid pET30a-GFP directly onto a thin layer of E. Coli, which was eventually taken up by 
these cells [70]. The suggested mechanism by which this occurred was evidenced by electron microscopy of cells. 
Under the microscope, the appearance of the cellular membrane appears compromised, providing a channel 
pathway for the entry of plasmid DNA. In contrast, analysis of the sprayed DNA shows this to be intact and 
unchanged. This method proved to be less destructive compared to other electrical methods used to generate pores 
in cells for internal delivery of biological molecules [71]. In comparison to several controls, the role of gold 
nanoparticles demonstrated a clear increase in activity. Although this demonstrated a different approach in 
electrospray encapsulation and delivery, the potential to use this technique in nanoparticle-assisted cell entry (via 
EHDA) exists (however several other factors need to be considered such as collecting medium) [70]. Electrospraying 
has also been used to generate bio-responsive polymer-peptides (genetically engineered elastin like polypeptides), 
with key emphasis on particle size variations (300-400 nm) based on the various parameters mentioned previously 
[72]. 
Emerging Chemistries- Nanotubes 
Current studies into carbon nanotubes have shown their potential emerging scientific applications across a wide 
remit [73]. The electrospray process has been adapted to prepare these structures in aerosol format with a potential 
view to utilise these in animal models [74]. Furthermore, decorated nanotubes [75] are a potential route for drug 
delivery, these structures can be coated (on the nano-scale) with colloidal systems using the electrospray process in 
a controlled manner [76]. Biological molecules (e.g DNA) can also be coated [77], suggesting a potential route of 
preparation via electrospray technology. 
NANOFIBRES 
While particles have been the primary focus of nanoscaled materials research, there is growing interest in nanofibres 
as potential carrier systems for API and biological molecules. Nanofibres present a large surface area (increased 
interaction). When prepared using the electrospinnng process, these structures can also be used to increase the 
solubility of poorly soluble APIs (rendering them amorphous) [44]. In addition to these, ambient temperature 
processing and enhanced topographies are also benefits in regenerative medicine. 
DNA Nanofibres 
While many APIs continue to be developed, several researchers are focusing on the use of genetic material as a 
means of tackling diseases largely driven by our growing understanding in the field. Some of the earliest experiments 
including DNA based electrospinning date as far back as 1997 based on thymus genomic DNA resulting in pure DNA 
fibres with diameters as small as 30nm [78]. Later studies have focused more on the inclusion of polymeric systems 
alongside these materials to prepare fibres or matrix systems with one focusing on lambda DNA (a medium size 
E.coli bacteriophage used as a model system for regulated site-specific recombination) spun alongside PEO. These 
fibres possessed diameters between 100-350 nm with the DNA appearing stretched [79], whereas a later study has 
shown size variations (50-250 nm) based on the same system (PEO and DNA) achieved by altering processing 
parameters such as flow rate, applied voltage and deposition distance. Such matrix systems have potential in 
advanced cell culturing related applications (including tissue scaffold engineering). 
Biomacromolecules as 3D Matrix Systems 
Electrospinning techniques have been used to prepare scaffolds of fibre-based systems with other biological 
molecules. Some materials (such as collagen) have been used extensively in this form of matrix preparation as well 
as various other tissue engineering routes, largely due to their biocompatibilities and resemblance to existing 
structures in the body. For example collagen extracted from calfskin type (I) has been used to prepare nanofibres 
with diameters in the region of ~100 nm. Within the same work, the importance of fibre orientation for mechanical 
property control was also demonstrated [80]. More recently, a comparison of electrospun collagen fibres and their 
native structures focused on the type of solvent system used to prepare the former. The findings demonstrated 
variations arising in some segments (folded or unfolded) of the protein based on the solvent system (e.g. 
fluorinated) which highlights the importance of material and solvent selection [81]. While collagen may be the 
material of choice, it has also been utilised as a composite material. One such study has combined collagen peptides 
with chito-oligosaccharides (2:1 ratio respectively) to generate electrospun nanofibres in the range of 50-100nm. 
These fibres demonstrated enhanced anti-bacterial properties with potential applications in wound care [82]. 
Numerous other examples of composite fibres based on biomacromolecules exist, with one in particular (gelatin-
polycaprolactone (PCL), mean fibre diameter ~250 nm) coating their surfaces with nano-gold particles (using 
evaporation with resulting nanocomposite thickness in the range 2-14nm). In-vitro tests using cell lines 
demonstrated the potential of these fibres in cardiac tissue engineering [83]. 
API Impregnation into Matrix (Polymeric Network) 
Numerous examples of drug loaded (API) polymeric nanofibers have been established. For example, amphotericin B 
(an anti-fungal drug, at 1 wt.%) has been encapsulated in nanofibres with an average diameter of 100 nm using a 
base formulation comprising gelatin/acetic acid/water [84]. However, the selection of material is not limited to pure 
polymeric base systems. Ultra-thin nano-fibres 
with high drug loading ability and diameter below 100 nm were generated using mesoporous materials (TS-1 
zeolite). Unlike conventional pure polymer matrix systems, this system was capable of drug loading and release 
based on the superabsorbent nature of the fibres prepared coupled with the electrostatic properties arising from the 
metallic ions of TS-1 [85]. In addition to this, these fibres were also able to demonstrate prolonged release of drug, 
which is an area of ongoing interest in pharmaceutical technologies. Some fibrous structures can also exist in a 
variety of dosage formats. For example, nanofibres based patches can be developed based on multiple phases (solid 
or liquids) enabling alterations or control on the release mechanism of actives. As the multiple phases exist, it also 
permits controlled multiple drug loading and release [86]. There is ample work in various segments of the 
electrospinning process in relation to active encapsulation, including focus on active type, matrix system and device 
used to prepare nanofibre systems [13]. Although the vast majority of these systems seem simple (diffusion based 
release) the focus is to utilise versatile excipients or additional smart material components of the fibre so the release 
of actives is driven by external triggers. One such preparation has shown the sharp controlled release of dextran 
from relatively coarse (600-700 nm) nanofibre systems (formulated with copolymers of N-isopropylacrylamide and 
N-hydroxymethylacrylamide) based on temperature responsive mechanisms [87]. 
Bioactive Ceramics 
Due to advances in science and adequate healthcare, there is an increase in age longevity, which also results in more 
orthopaedic related complications (natural ageing). An increase in demand for implantable devices has also led to an 
increase within this area. Ceramic bioactive and biocompatible materials (e.g. hydroxyapatite (HA) and silica 
possessing specific crystal phases and surface chemistry) coupled to unravelling of cell-topographical (roughness, 
size and chemistry) interactions have led to several explorations using electrospun and electrosprayed systems 
utilising silica and application related nano-scaled materials [88, 89]. Titania is used as a biocompatible surface for 
titanium implants, and silica is considered to have good biological performance. Using electrospinning (followed by 
heat treatment), nanoscaled titania based ceramic fibres (100-300nm) have been prepared. The morphologies and 
resulting crystal phases of these fibres can be varied based on the initial polymer concentration [90]. One such 
material considered the gold standard is hydroxyapatite (HA), and is often utilised as ceramic nanoparticles or as a 
composite material due to poor mechanical properties. Electrospun fibres make use of these nano-features 
(<100nm) and can be used (along with the fibrous matrix) for enhanced cellular growth [91]. In most studies the 
focus has centred on the inclusion (physically mixed) of a bioactive material (like nano-scaled HA) to serve a 
functional role. It is also possible, however, to chemically link nanoceramics to polymeric fibres by utilising a 
covalently coupled nHA–polymer (e.g. polyurethane) processing solution [92]. Electrospinning has also been used to 
prepare HA nanoparticles from coarser sizes (from 1440 to <100nm in size) [93]. Finally, while the chemical and 
nano-features of bioactive materials like HA are accommodated within the polymeric matrix, multi-active fibres can 
also be prepared to enhance the biocompatibility of implantable devices e.g. also release actives to prevent or 
control resulting infections [44]. 
 
SUMMARY 
A summary of key EHDA engineered fibre and particle systems is summarised in Table 1. 
CONCLUDING REMARKS 
Various EHDA methods and techniques based on the underlying principles have delivered structures with potential 
applications as nanomedicines. The scaling up of such fabrication routes has shown to be possible and able to 
produce commercially viable quantities. Coupled to this, ambient condition processing and minimal damage to 
selected materials (including APIs and cells) provides numerous options in the ongoing development of future 
medicines. The current status of nanomedicines prepared via EHDA engineering is still at the interface of emerging 
and exploratory science. Numerous successful animal and in-vitro models have been demonstrated. In addition, 
from a commercial materials viewpoint, the scalable potential has been proven, potentially enabling the mass scale 
production of nanomedicines that are proven to be effective in future clinical trials. 
Table 1. A summary of selected EHDA engineered nanomedcines. 
Drug/API/ Molecule Polymer/ 
Matrix 
 
Morphology 
 
Size 
In-vitro/In-
vivo 
Models 
 
Process 
 
Outcome/Notes 
 
Ref. 
 
Insulin 
 
PLGA 
 
Particulate 
 
100nm 
 
In-vitro release 
using SBF 
 
Co-axial spray 
Encapsulation of insulin and 
excipients into biodegradable 
nanoparticles at ~80% 
efficiency using a co-axial 
system. Release of insulin can 
be controlled using excipient 
 
 
62 
 
Budesonide and 
epigallocatechin 
gallate 
 
PLGA 
 
Particulate 
 
160nm-1.2 
µm 
 
In-vitro release 
using PBS 
 
Co-axial spray 
Encapsulation of budesonide 
and epigallocatechin gallate 
and excipients into 
biodegradable particles at ~90-
95% and 88-92% efficiency 
respectively 
 
63 
 
Beclomethasone- 
dipropionate and 
salbutamol- sulfate 
 
PLA 
 
Particulate 
 
200nm 
 
- 
 
Co-axial spray 
but outer 
needle is gas 
Nitrogen gas fed around the 
capillary exit to enhance the 
evaporation rate of solvent. 
The modified process achieved 
be- tween 54-56% 
 
 
61 
 Paclitaxel 
 
PCL/PLGA 
 
Particulate 
 
300nm-15 µm 
 
In-vitro release 
using PBS 
 
Single spray 
Encapsulation of paclitaxel and 
excipients into biodegradable 
nano- and micro- particles at 
~80% 
 
65 
 
Gemcitabine 
 
Folate-
chitosan 
 
Particulate 
 
200-300nm 
 
Various pH 
envi- ronments 
for re- lease 
pro- 
 
  
 
 
Co-axial spray 
Encapsulation of gemcitabine 
and excipients (folate 
conjugated)  into 
biodegradable core shell 
nanoparticles with 
encapsulation up to ~85% with 
     
 
66 
 
Tamoxifen 
 
PAA-chol 
 
Particulate 
 
500nm 
 
multicompart
mental 
 
 
 
Single spray 
Encapsulation of tamoxifen 
with drug loading of about 
40% w/w and the 
   
 
67 
 
Hydroxycamp- 
tothecin (HCPT) 
 
PGBELA 
 
Particulate 
 
230nm 
In-vitro release 
using PBS 
In-vivo model 
using 
intravenous 
   
 
 
 
 
Single spray 
 
HCPT entrapped into PGBELA  
at ~80% efficiency and 
extended release of HCPT. A 
superior in vivo antitumor 
     
   
 
68 
 
Plasmid DNA 
 
- 
(Au 
particle) 
 
Particulate 
 
50nm 
 
E. Coli 
 
Single spray 
Charged droplets of AU-
Plasmid DNA deposited 
directly on to cells and uptake 
optimised using buffer 
solutions. The role of metallic 
nanoparticles enhanced the 
plasmid transformation by up 
to ~7 fold. Plasmid not 
changed during the process 
but cellular membrane 
    
 
70 
 
Doxorubicin 
 
elastin-like 
polypeptid
es (ELP) 
 
Particulate 
 
300-400nm 
 
In-vitro release 
pH- mediated 
 
Single spray 
Molecular weight of ELP and 
the concentration of solution 
play an important role in 
morphologies of ELP particles. 
Non spherical structures 
resulted with low voltages and 
high flow rates (tailed 
structures). pH dependent 
solubility of ELP particles ob- 
served. 
 
72 
(Table 1) contd…. 
Drug/API/ 
Molecule 
Polymer/ 
Matrix 
 
Morphology 
 
Size 
In-vitro/In-vivo 
Models 
 
Process 
 
Outcome/Notes 
 
Ref. 
 
Lambda DNA 
 
Polyethylene 
oxide (PEO) 
 
Fibres 
 
100-350nm 
 
--- 
 
Electrospinning 
single needle 
PEO Nanofibers containing 
isolated stretched DNA mole- 
cules produced. This technique 
opens up possibilities in novel 
sequencing techniques and 
char- acterization of elastic 
properties of sections of DNA 
 
 
79 
 
Collagen 
 
- 
 
Fibres 
 
100nm 
 
Bioreactor process 
using aortic cell 
lines. 
 
Electrospinning 
single needle 
Size dependent on 
concentration of polymer in 
solvent (HFP). Method to 
prepare scaffolds. Cells 
densely populated these 
structures within 7 days of 
incu- bation and are integrated 
within the fibrous matrix- ideal 
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Fish scale colla- 
gen peptides 
 
Chito- 
oligosaccharide 
 
Fibres 
 
50-100 nm 
Antimicrobial 
properties using S. 
Aureus and Human 
skin fibroblast 
viability 
 
Electrospinning 
single needle 
Peptides utilised are potential 
actives in wound dressings, 
although ratios between 
compo- nents are crucial. To 
allow fibre formation PVA was 
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Fibres 
containing 
gold 
nanoparticles 
 
2, 4 and 14 
nm (embed- 
deon 250 nm 
fibres) 
Cardiac cells from 
neonatal rats 
Electrospinning 
single needle 
Spun polymeric fibres coated 
with gold particles via 
evapora- tion process. 
Compared to pure fibres, gold 
coated samples lead to 
increased expression of 
cardiac sacromeric actinin. 
Greater contraction amplitude 
observed with nanoparticle 
   
  
83 
 
Cefoxitin (so- 
dium salt) 
 
TS1-Zeolite 
(mesoporous 
material) with 
poly(butylenes 
succinate) 
 
Fibres 
 
~100nm 
Phosphate 
buffered saline 
L929 Fibroblasts 
(mouse) 
S. aureus and K. 
pneumonia 
 
 
 
Electrospinning 
single needle 
Fibres containing mesoporous 
materials can be used a drug 
delivery system. The inclusion 
of these materials assists in 
antibac- terial activity (99.9 %) 
due to metallic ions. TS1-
Zeolite loaded at 0.1 wt%. 
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Betamethasone 
acetate 
 
Polymethyl- 
silsesquioxane 
and Polylactic- 
co-glycolic acid 
 
Fibres con- 
taining liquid 
and particles 
 
Down to 50- 
500nm and 
encapsulatio
n in 2-3µm 
hollow tubes 
 
- 
 
Electrospraying 
(single needle) and 
Electrospinning Co-
axial 
Concept paper on preparation 
of PLGA nanoparticles 
containing Betamethacone 
acetate. These encapsulated 
into micron scale hollow tubes 
using a liquid filled formulation 
in the tubular con- structs. 
Incorporation into dress- ings 
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Hydroxyapatite 
(HA) and Indo- 
metha- 
cin/Ibuprofen 
 
Polycaprolac- 
tone 
 
Fibres with 
drug and 
bioactive 
component 
(nano- 
particles) 
 
400nm-20 
µm 
 
PBS 7.4 
and SBF for miner- 
alisation studies 
 
Electrospinning 
Single needle 
Fibres demonstrate multiple 
functions. Controlled release 
of drugs from the structures 
based on fibre size and 
minerlisaiton due to the 
presence of nHA embedded 
within them. Encapsu- lati0on 
effeicncy for drugs was ~ 7-
10%. Drugs incorporated in an 
amorphous state. 
 
44 
 
 
 
Drug/API/ 
Molecule 
Polymer/ 
Matrix 
 
Morphology 
 
Size 
In-vitro/In-vivo 
Models 
 
Process 
 
Outcome/Notes 
 
Ref. 
 
Hydroxyapatite 
(HA) 
 
Genipin and 
chitosan 
 
Fibres em- 
bedded with 
HA particles 
 
Between 228- 
335 nm 
 
Osteoblast like 7F2 
cells. 
 
Electrospinning 
Single needle 
Cross linking of fibres with 
genepin increased their size 
but also increased their 
mechanical properties 
significantly. Matching that of 
the natural host environ- 
ment. HA increased the os- 
teonectin mRNA expression. 
The concentration of nHA was 
varied (0.8, 1 and 2%) and 
genepin  cross linker was used 
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 Hydrpxyapatite 
(HA) 
 
Polyurethane 
(PU) 
 
Fibres cova- 
lently bound 
to HA 
 
~300nm 
 
- 
 
Electrospinning 
Single needle 
Chemical linking of nHA to 
polymer system as opposed to 
general processing utilising a 
mixture. A chemically bound 
nHA-PU solution was first syn- 
thesised and then directly 
spun. Mechanical properties of 
PU can be adjusted while 
bioactive properties of matrix 
provided by HA. 
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Hydroxyapatite 
(HA) 
 
Polyvinyl 
butyral 
 
Coarse fibres 
converted 
into nanopar- 
ticles 
 
<100nm 
(resulting 
particles) 
 
SBF for mineralisa- 
tion of fibres 
 
Electrospinning 
Single needle 
Polymeric fibres spun as a 
com- posite with micron 
scaled HA with fibre diameters 
of ~1µm. After calcination (600 
ºC) fibres result in nano-scaled 
HA (<100nm- ~64% of all HA 
pre- sent by DLS, while TEM 
sug- gests 90% less than 
50nm). The reduced size is 
more favourable and this can 
achieved by the addition of an 
anionic SDS surfactant (96% 
below 100nm). 
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LIST OF FIGURES 
Fig. (1). A diagramatic representation of jet formation showing some of the various forces involved. 
Fig. (2). Selected jetting modes showing (a) no flow from needle exit (b) conventional micro-dripping from needle 
exit (low electricfield/ applied voltage) (c) unstable jetting (approaching near optimal electric field) and (d) stable 
spraying (optimised applied voltage), [the scale bars are 5mm]. 
Fig. (3). Basic electrohydrodynamic (EHDA) set-up (the scal bar is 5mm). 
Fig. (4). Structural variations due to process and material parameters. 
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